Julie A. Patterson

Aug 13, 2024 | ajmc.com | Julie A. Patterson |Jonathan D. Campbell

PublicationArticleAugust 13, 2024The American Journal of Managed CareAugust 2024Author(s):This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions. Am J Manag Care.

Jun 5, 2024 | healthaffairs.org | Julie A. Patterson |James Motyka |Jonathan D. Campbell |John O’Brien

Since , states have enacted prescription drug affordability boards (PDAB) with the asserted intention of lowering drug spending and improving affordability for patients. Variability across states and uncertainty surrounding the implementation of PDAB processes raise questions about the downstream consequences of state governments setting maximum reimbursement rates for drugs purchased in their state.

Feb 2, 2024 | ajmc.com | Julie A. Patterson |James Motyka

ABSTRACTObjectives: To describe the clinical development landscape for high-spend Medicare Part D small molecule drugs and illustrate the potential impact of the Inflation Reduction Act of 2022 (IRA) on research and development investments toward subsequent indications.

Nov 3, 2023 | healthaffairs.org | John O’Brien |Julie A. Patterson |James Motyka

Clinical development programs for new drugs include an array of research conducted both before and after a drug’s initial approval by the Food and Drug Administration (FDA). Post-approval clinical trials may be conducted in new patient populations to support additional indications and to demonstrate long-term safety and efficacy, including impacts on overall survival or major health events.